<DOC>
	<DOC>NCT00451555</DOC>
	<brief_summary>The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help patients who have breast cancer and make the tumor smaller or disappear and for how long.</brief_summary>
	<brief_title>Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Female patients with a histologicaldocumented diagnosis of locally advanced or metastatic breast cancer. The primary or metastatic tumor must be ER and/or PtR receptor positive. Note: Hormone receptor positivity is defined as ER or PtR greater than 10 fmol/mg by biochemical assay or 10% positive cells by immunohistochemistry Patients are resistant to AI therapy Females with postmenopausal status Previous radiation therapy is allowed, but should have been limited Measurable or nonmeasurable disease Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale Have adequate organ function Have an estimated life expectancy of at least 24 weeks Must sign an informed consent document Have had prior treatment with fulvestrant or enzastaurin Are receiving concurrent administration of any other antitumor therapy, with the exception of gonadotropinreleasing hormone (GnRH) antagonists. Have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry Have received supplemental estrogen or progesterone within 4 weeks prior to study entry Are HER2positive Are unable to discontinue use of anticoagulants Have hypercalcemia Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment Have documented central nervous system (CNS) metastases, symptomatic pulmonary lymphangitis, or involvement of more than 1/3 of the liver Have a serious concomitant systemic disorder Have a serious cardiac condition Are unwilling or unable to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy Are unable to swallow tablets.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>